RAD Integrins technology featured in Cancers journal
Filed with ASX · · 2 pages · English
Radiopharm Theranostics(ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses,is pleased to announce its best in class avꞵ6 Integrin platform technology has been featured in prestigious research journalCancers. Radiopharm’s avꞵ6 platform was invented by highly regarded Integrin expert Professor Johann
Radiopharm Theranostics Limited on 6ix
Later from Radiopharm Theranostics
- RAD acquires IP Ownership of Radiopharmaceutical Nanobodies
- Radiopharm and TerraPower sign Actinium 225 agreement
- LOI with GenesisCare to start first trial in Australia
- RAD Licenses UCLA Dual Action Antibody
- FDA grants Orphan drug status to RAD DUNP19 for Osteosarcoma
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics